Other names: FRP-4; sFRP-4; FRPHE; MGC26498; LOC6424 HGNC (Hugo): SFRP4 Location: 7p14.1 Local order: According to NCBI, SFRP4 is telomeric to EPDR1 (7p14.1) ependymin related protein 1 (zebrafish) and STARD3NL (7p14-p13) StAR-related lipid transfer domain containing 3 N-terminal like and centromeric to TXNDC3 (7p14.1) thioredoxin domain containing 3 (spermatozoa) and GPR141 (7p14.1) G protein-coupled receptor 141.
Diagram illustrates the full length SFRP4 protein which contains a signal peptide sequence of 20-30 amino acids, a cysteine-rich domain (CRD) of approximately 120 amino acids, and a netrin-related motif (NTR) domain. Conserved cysteines of the CRD are indicated by *.
These cysteines form a pattern of disulfide bridges. The C-terminal portion of the SFRP protein is characterized by segments of positively charged residues that appear to confer heparin-binding properties in at least two SFRPs (SFRP1 and SFRP3) and contains a netrinrelated motif (NTR) with six cysteine residues that most likely form three disulfide bridges. NTR domains with similar features are found in a wide range of unrelated proteins, including Netrin-1, tissue inhibitors of metallo-proteinases (TIMPs), complement proteins and type I procollagen C-proteinase enhancer proteins (PCOLCEs). The six conserved cysteines in the NTR of SFRP4 share a similar spacing to SFRP3, whereas those of the SFRP1/SFRP2/SFRP5 subgroup are distinctively different, indicating a disparity in disulfide bond formation. Uniquely, SFRP4 contains two additional cysteine residues. The overall function of the NTR is unknown, yet there is some evidence that the NTR may also play a role in Wnt binding. This implies that multiple Wnt binding sites may exist on SFRP molecules and/or that SFRPs exhibit differential affinities for Wnt ligands according to the different SFRP conformational and post-translational modifications.
Expression
SFRP4 is expressed in various normal tissues including endometrium (specifically stromal cells with higher expression during proliferative phase of menstrual cycle), ovary, kidney, heart, brain, mammary gland, cervix, pancreas, stomach, colon, lung, skeletal muscle, testis, eye, bone, prostate, and liver.
Localisation
Secreted from cell; extracellular matrix; bound to plasma membrane.
Function
Since SFRPs share a similar CRD with the Fzd family of receptors; it is believed that SFRPs may act as soluble modulators that compete with Fzd to bind the Wnt ligands, thereby altering the Wnt signal. Individual SFRPs also have distinct binding specificity for distinct Wnt ligands. Reports have demonstrated that SFRP4 binds Wnt7a and there is conflicting data for SFRP4 binding to Wnt3a. SFRP4 expression is regulated by estrogen and progesterone and may act as a regulator of adult uterine morphology and function. SFRP4 has been shown to increase apoptosis during ovulation. Transgenic studies have found that SFRP4 decreases bone formation and inhibits osteoblast proliferation by attenuating canonical/beta-catenin-Wnt signaling. SFRP4 reportedly exhibits phospha-turic effects by specifically inhibiting sodium-dependent phosphate uptake.
Homology
Of the five human SFRPs (SFRP1, SFRP2, SFRP3, SFRP4, SFRP5), SFRP4 shares most significant homology with SFRP3.
Mutations

Note
It was reported that the T allele of the SFRP4 gene polymorphism ARG262 (CGC to CGT) of exon4 is associated with decreased bone mineral density in postmenopausal Japanese women.
Implicated in
Endometrial Carcinoma
Note SFRP4 was more frequently down-regulated in (microsatellite instability). MSI cancers as compared with (microsatellite stable) MSS endo-metrioid endometrial cancers. Expression of SFRP4 is decreased in both low-grade endometrial stromal sarcoma and undifferentiated endometrial sarcoma.
Malignant Pleural Mesothelioma
Note SFRP4 promoter is frequently methylated in this cancer leading to inhibition of expression and is associated with abnormal growth; restoration of SFRP4 results in growth suppression and apoptosis in mesothelioma cell lines.
Tumor-induced osteomalacia
Note Tumor-induced osteomalacia is a disorder in which there is an increase in renal phosphate excretion and a reduction in serum phosphate levels leading to hyperphosphaturia, hypophosphatemia and rickets.
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SFRP4 is highly expressed in such tumors and functions as a circulating phosphaturic factor that antagonizes renal Wnt-signaling.
Breast Cancer
Note Studies have found evidence for SFRP4 overexpression in breast cancer.
SFRP4 (Secreted Frizzled-Related Protein 4)
Carmon KS, Loose DS Atlas Genet Cytogenet Oncol Haematol. 2010; 14(3) 
Pancreatic Cancer
Note SFRP4 found to be significantly hypermethylated in the tumors of cancer patients versus matched adjacent tissue controls.
Gastric Carcinoma
Note
The SFRP4 was highly methylated in gastric carcinoma samples with greater instance in H. pylori positive patients.
Prostate Cancer
Note SFRP4 is overexpressed in prostate cancers and functions to inhibit cell proliferation and metastatic potential. Prognosis Increased expression of membranous SFRP4 is associated with a good prognosis in human localized androgen-dependent prostate cancer, suggesting a role for sFRP4 in early stage disease.
B-cell chronic lymphocytic leukemia
Note SFRP4 was found to be frequently methylated and downregulated in CLL samples.
Colorectal Carcinoma
Note SFRP4 expression was shown to be up-regulated in colorectal cancer.
Esophageal Adenocarcinoma
Note SFRP4 mRNA and protein expression were significantly decreased due to hypermethylation in esophageal adenocarcinoma and Barrett's esophagus patients.
